CGTN: Tibetan Religious Leader Extends Wishes for Spring Festival, Tibetan New Year
12.2.2021 16:50:00 EET | Business Wire | Press release
The Tibetan New Year falls on the same day as the Spring Festival this year. As a long, bitter winter starts petering down, colorful spring sneaks in.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210212005297/en/
Bainqen Erdini Qoigyijabu, the 11th Panchen Lama, on Friday expressed best wishes to all Tibetans at home and abroad for both the Spring Festival and the Tibetan Year of the Iron Ox through China Media Group (CMG) and China Tibet Online.
Looking back at the past year, he expressed his affirmation that China has overcome difficulties in the face of the pandemic. "The whole country united together, and all people worked with one heart, achieving outstanding results in preventing and controlling the COVID-19 pandemic, which draws much worldwide attention," he said.
"From the pandemic, we have further understood how precious life is. As I see it, health, peace and happiness are the most precious fortune in human life. From the pandemic, we have also further understood that all human beings are in a community with a shared future."
He also expressed his understanding of the importance of a community with a shared future for mankind.
Erdini Qoigyijabu spoke of the historic alleviation of poverty in Tibet and of people in the region living and working in peace and contentment, and expressed his sincere gratitude to the country. "I feel very gratified to see the new Tibet today," he said. "A glorious time and a happy homeland is not a gift from nature. We should remain grateful for our country, and for the thousands upon thousands of people willing to sacrifice for us.”
Finally, he offered New Year blessings to the people of the whole country. "Let us jointly wish and pray the world be peaceful, the country be prosperous, the people live in peace, the weather be favorable, and all living things live joyfully! I wish everyone and every family be happy, safe and sound in the New Year and reap a new harvest," he concluded.
The Tibetan New Year, known as Losar, is the most important festival on the Tibetan calendar.
Celebrating Losar, Tibetan New Year, on the plateau
Losar is roughly the same as the Spring Festival of the Han ethnic group.
The Tibetan New Year is calculated based on the Tibetan calendar. It starts on the first day of the first month of the Tibetan calendar and ends on the 15th day. It falls on February 12 this year.
Originally a harvest celebration, the festival gradually shifted to the beginning of a new year, after Princess Wencheng of the Tang Dynasty (618-907) married Songtsen Gampo, the then Tibetan King, and brought to the southwestern Chinese region the culture of the Han people.
For the Tibetans and those who have been exploring the Tibetan New Year on the plateau, Tashi delek, and Happy New Year!
A developing Tibet
Transportation has long been a bottleneck inhibiting Tibet's development, as the region is situated on the Qinghai-Tibet Plateau with complex geographical conditions for road construction and limited technology and funds.
Since late 2012, China has been bolstering its infrastructure investment in Tibet. So far, roads have connected 95 percent of the township-level administrations and 75 percent of the incorporated villages in the region. The road network in Tibet now stretches over 117,000 kilometers, up by 50 percent from the end of 2015.
As for air transportation, Tibet has launched a total of 130 air routes, with 61 cities connected by flights; 5.18 million passenger trips were registered in 2020.
The development of Tibet is well-founded with data.
With the strong support of the central government and the active assistance from the local people, the economy of Tibet has been developing steadily.
In 2018, Tibet registered a GDP growth rate of 10 percent, the highest in China.
According to the released work reports from the local governments in February 2021, Tibet led the 2020 growth rate among the country's 31 provincial-level regions, at 7.8 percent, followed by southwestern provinces of Guizhou and Yunnan, at 4.5 and 4 percent, respectively.
In 2021, Tibet's GDP growth target stands at over 9 percent, while the pace is set around 8 percent for Guizhou and Yunnan provinces.
Original article: here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210212005297/en/
Contact information
Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
